Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchPVP-IPovidone-Iod.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Povidone-Iodine for COVID-19: real-time meta analysis of 21 studies

@CovidAnalysis, May 2024, Version 36V36
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mohamed (RCT) 86% 0.14 [0.01-2.21] viral+ 0/5 3/5 Improvement, RR [CI] Treatment Control Choudhury (RCT) 88% 0.12 [0.03-0.50] death 2/303 17/303 Choudhury (RCT) 84% 0.16 [0.09-0.28] hosp. 12/303 77/303 Choudhury (RCT) 96% 0.04 [0.02-0.07] viral+ 8/303 213/303 Guenezan (RCT) 63% 0.37 [0.06-1.63] viral load 12 (n) 12 (n) Elzein (DB RCT) 89% 0.11 [0.01-1.00] viral load 25 (n) 9 (n) Short term viral Arefin (RCT) 79% 0.21 [0.08-0.54] viral+ 4/27 19/27 Short term viral Arefin (RCT) 89% 0.11 [0.03-0.41] viral+ 2/27 19/27 Short term viral Arefin (RCT) 53% 0.47 [0.26-0.85] viral+ 9/27 19/27 Short term viral Arefin (RCT) 80% 0.20 [0.09-0.44] viral+ 5/27 25/27 Short term viral Arefin (RCT) 64% 0.36 [0.21-0.62] viral+ 9/27 25/27 Short term viral Arefin (RCT) 74% 0.26 [0.19-0.37] viral+ 29/135 44/54 Short term viral Pablo-Marcos 29% 0.71 [0.32-1.56] viral load 31 (n) 40 (n) Pablo-Marcos 9% 0.91 [0.20-4.16] viral load 31 (n) 40 (n) Sulistyani (SB RCT) 6% 0.94 [0.45-1.96] viral load 15 (n) 15 (n) Sulistyani (SB RCT) 11% 0.89 [0.42-1.88] viral load 15 (n) 15 (n) Elsersy (DB RCT) 91% 0.09 [0.01-1.62] hosp. 0/100 5/100 CT​2 Elsersy (DB RCT) 15% 0.85 [0.76-0.96] recov. time 100 (n) 100 (n) CT​2 Elsersy (DB RCT) 49% 0.51 [0.42-0.62] recov. time 100 (n) 100 (n) CT​2 Elsersy (DB RCT) 48% 0.52 [0.43-0.63] recov. time 100 (n) 100 (n) CT​2 Elsersy (DB RCT) 68% 0.32 [0.22-0.49] viral+ 21/100 65/100 CT​2 Elsersy (DB RCT) 90% 0.10 [0.01-0.77] viral+ 1/100 10/100 CT​2 Elsersy (DB RCT) 29% 0.71 [0.62-0.81] viral+ 70/100 99/100 CT​2 Elsersy (DB RCT) 92% 0.08 [0.05-0.14] transmission 12/194 173/227 CT​2 Elsersy (DB RCT) 94% 0.06 [0.03-0.12] transmission 8/194 157/227 CT​2 Sevinç Gül (RCT) 99% 0.01 [0.00-439] viral load 21 (n) 20 (n) Short term viral OT​1 Natto (RCT) 74% 0.26 [0.03-2.76] viral load 12 (n) 12 (n) Short term viral OT​1 Natto (RCT) 96% 0.04 [0.00-2.26] viral load 12 (n) 12 (n) Short term viral OT​1 Natto (RCT) 44% 0.56 [0.07-4.53] viral load 12 (n) 12 (n) Short term viral OT​1 Sirijatuphat 33% 0.67 [0.17-2.67] viral load 12 (n) 12 (n) Short term viral Sirijatuphat 88% 0.12 [0.02-0.94] viral load 12 (n) 12 (n) Short term viral Sirijatuphat 83% 0.17 [0.02-1.49] viral load 12 (n) 12 (n) Short term viral Baxter (RCT) -214% 3.14 [0.13-74.7] hosp. 1/37 0/42 OT​1 Baxter (RCT) 57% 0.43 [0.20-0.94] no recov. 6/27 18/35 OT​1 Baxter (RCT) 14% 0.86 [0.27-2.76] transmission 4/27 6/35 OT​1 Karaaltin (RCT) 83% 0.17 [0.05-0.62] viral load 30 (n) 30 (n) Karaaltin (RCT) 86% 0.14 [0.05-0.46] viral load 30 (n) 30 (n) Karaaltin (RCT) 82% 0.18 [0.02-1.71] viral load 30 (n) 30 (n) Karaaltin (RCT) 91% 0.09 [0.03-0.30] viral load 30 (n) 30 (n) Matsuyama (RCT) 69% 0.31 [0.10-0.93] viral+ 4/139 13/140 Matsuyama (RCT) 38% 0.62 [0.42-0.92] viral+ 139 (n) 140 (n) Friedland (DB RCT) 60% 0.40 [0.18-0.93] viral load 10 (n) 13 (n) Friedland (DB RCT) 52% 0.48 [0.25-0.92] viral load 10 (n) 13 (n) Seneviratne (RCT) 33% 0.67 [0.50-0.91] viral load 4 (n) 2 (n) Short term viral Zarabanda (RCT) -27% 1.27 [0.26-6.28] no recov. 3/13 2/11 OT​1 Zarabanda (RCT) -50% 1.50 [0.31-7.30] no recov. 3/11 2/11 OT​1 Zarabanda (RCT) 0% 1.00 [0.19-5.24] viral+ 2/7 2/7 OT​1 Jamir (ICU) 57% 0.43 [0.27-0.69] death 39/163 62/103 ICU patients Ferrer (RCT) 34% 0.66 [0.02-19.0] viral load 9 (n) 12 (n) Short term viral Ferrer (RCT) 93% 0.07 [0.00-17.4] viral load 9 (n) 9 (n) Short term viral Fantozzi (RCT) 31% 0.69 [0.39-1.21] viral+ 5/8 10/11 Short term viral OT​1 Fantozzi (RCT) 59% 0.41 [0.18-0.96] viral+ 3/8 10/11 Short term viral OT​1 Seet (CLUS. RCT) 45% 0.55 [0.38-0.80] symp. case 42/735 64/619 OT​1 Seet (CLUS. RCT) 31% 0.69 [0.52-0.92] cases 338/735 433/619 OT​1 Povidone-iodine COVID-19 outcomes c19early.org May 2024 1 OT: comparison with other treatment2 CT: study uses combined treatment Favors povidone-iodine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit